Severe HIV-associated hypertriglyceridaemia treated with rosuvastatin plus omega-3 fatty acids

International Journal of STD and AIDS

Volumn 20, Issue 8, 2008, Pages 580-581

  Falasca, K ^a   Ucciferri, C ^a   Mancino, P ^a   Pizzigallo, E ^a   Calza, L ^b   Vecchiet, J ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

HIV; Hypertriglyceridaemia; Omega 3; Rosuvastatin

Indexed keywords

ATAZANAVIR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; ROSUVASTATIN; TRIACYLGLYCEROL; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; MALE; METABOLIC PARAMETERS; PRIORITY JOURNAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; DRUG THERAPY, COMBINATION; FATTY ACIDS, OMEGA-3; FLUOROBENZENES; HIV INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; MALE; PYRIMIDINES; SULFONAMIDES;

EID: 70349238767     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2008.008419     Document Type: Article

References (19)

1. Oh J, Hegele RA. HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis 2007;7:787-796
2. Fessel WJ, Follansbee SE, Rego J. High-density lipoprotein cholesterol is low in HIV-infected patients with lipodystrophic fat expansions: implications for pathogenesis of fat redistribution. AIDS 2002;16:1785-1789
3. Calza L, Manfredi R, Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 2004;53:10-14 (Pubitemid 38072177)
4. Rimland D, Guest JL, Hernandez-Ramos I, Del Rio C, Le NA, Brown WV. Antiretroviral therapy in HIV-positive women is associated with increased apolipoproteins and total cholesterol. J Acquir Immune Defic Syndr 2006;42:307-313 (Pubitemid 44050008)
5. Falasca K, Manigrasso MR, Racciatti D, et al. Associations between hypertriglyceridemia and serum ghrelin, adiponectin, and IL-18 levels in HIV-infected patients. Ann Clin Lab Sci. 2006;36:59-66 (Pubitemid 43805880)
6. Guardiola M, Ferre R, Salazar J, et al. Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T → C gene variation. Clin Chem 2006;52:1914-1919
7. Falasca K, Ucciferri C, Manzoli L, et al. Metabolic syndrome and cardiovascular risk in HIV-infected patients with lipodystrophy. Int J Immunopathol Pharmacol 2007;20:519-527 (Pubitemid 47531055)
8. Friis-Moller N, Reiss P, Sabin CA, et al. Data collection on adverse events of anti-HIV drugs (DAD) study group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-1735
9. Kell P. The metabolic syndrome in HIV-seropositive patients. Int J STD AIDS 2007;18:507-508
10. Cahn PE, Gatell JM, Squires K, et al. Atazanavir - a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials. J Int Assoc Phys AIDS Care 2004;3:92-98
11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421
12. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003;37:613-627
13. Bullano MF, Wertz DA, Yang GW, et al. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Pharmacotherapy 2006;26:469-478
14. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-1861
15. Woods MN. Role of n-3 fatty acids in prevention of disease complications in patients with HIV. Nutr Clin Care 2005;8:24-30
16. Manfredi R, Calza L, Chiodo F. Polyunsaturated ethyl esters of n-3 fatty acids in HIV-infected patients with moderate hypertriglyceridemia: comparison with dietary and lifestyle changes, and fibrate therapy. J Acquir Immune Defic Syndr 2004;36:878-880 (Pubitemid 38859356)
17. Garber JG, Kitch DW, Fichtenbaum CJ, et al. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr 2008;47:459-466
18. Lee JH, O'Keefe JH, Lavie CJ, Marchioli R, Harris WS. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc 2008;83:324-332
19. Busti AJ, Bain AM, Hall RG II, et al. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol 2006;51:605-610